Cingulate Inc. Operating Cash Flow
Cingulate Inc. (CING) reported Operating Cash Flow of -$12.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- Cingulate Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$5.90M.
- Cingulate Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$6.91M.
- Cingulate Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$3.60M.
- Cingulate Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.24M.
- Cingulate Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$17.25M.
- Cingulate Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$18.45M.
- Cingulate Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$15.03M.
- Cingulate Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$15.88M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$5.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$12.81M 10-Q · filed 2026-08-13 | -$16.41M derived: sum of 3 quarters · filed 2026-08-13 | -$20.65M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$6.91M 10-Q · filed 2026-05-14 | -$10.51M derived: sum of 2 quarters · filed 2026-05-14 | -$14.75M derived: sum of 3 quarters · filed 2026-05-14 | -$19.55M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$3.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$7.84M derived: sum of 2 quarters · filed 2026-03-18 | -$12.64M derived: sum of 3 quarters · filed 2026-08-13 | -$17.25M 10-K · filed 2026-03-18 |
| 2025-09-30 | -$4.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$9.04M derived: sum of 2 quarters · filed 2026-08-13 | -$13.65M 10-Q · filed 2025-11-13 | -$17.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$4.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$9.40M 10-Q · filed 2026-08-13 | -$13.48M derived: sum of 3 quarters · filed 2026-08-13 | -$17.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$4.61M 10-Q · filed 2026-05-14 | -$8.69M derived: sum of 2 quarters · filed 2026-05-14 | -$12.57M derived: sum of 3 quarters · filed 2026-05-14 | -$14.31M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$4.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-18 | -$7.96M derived: sum of 2 quarters · filed 2026-03-18 | -$9.71M derived: sum of 3 quarters · filed 2026-03-18 | -$18.45M 10-K · filed 2026-03-18 |
| 2024-09-30 | -$3.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$5.63M derived: sum of 2 quarters · filed 2025-11-13 | -$14.37M 10-Q · filed 2025-11-13 | -$16.93M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$1.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-19 | -$10.49M 10-Q · filed 2025-08-19 | -$13.05M derived: sum of 3 quarters · filed 2025-08-19 | -$17.34M derived: sum of 4 quarters · filed 2025-08-19 |
| 2024-03-31 | -$8.75M 10-Q · filed 2025-05-08 | -$11.31M derived: sum of 2 quarters · filed 2025-05-08 | -$15.60M derived: sum of 3 quarters · filed 2025-05-08 | -$20.20M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$2.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | -$6.85M derived: sum of 2 quarters · filed 2025-03-27 | -$11.46M derived: sum of 3 quarters · filed 2025-03-27 | -$15.03M 10-K · filed 2025-03-27 |
| 2023-09-30 | -$4.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$8.90M derived: sum of 2 quarters · filed 2024-11-07 | -$12.47M 10-Q · filed 2024-11-07 | -$16.68M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$4.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$8.18M 10-Q · filed 2024-08-13 | -$12.39M derived: sum of 3 quarters · filed 2024-08-13 | -$15.79M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$3.58M 10-Q · filed 2024-05-08 | -$7.78M derived: sum of 2 quarters · filed 2024-05-08 | -$11.18M derived: sum of 3 quarters · filed 2024-05-08 | -$15.59M derived: sum of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | -$4.21M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | -$7.61M derived: sum of 2 quarters · filed 2024-04-01 | -$12.02M derived: sum of 3 quarters · filed 2024-04-01 | -$15.88M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$3.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$7.81M derived: sum of 2 quarters · filed 2023-11-13 | -$11.68M 10-Q · filed 2023-11-13 | -$16.30M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | -$4.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$8.28M 10-Q · filed 2023-08-14 | -$12.90M derived: sum of 3 quarters · filed 2023-08-14 | -$15.48M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$3.86M 10-Q · filed 2023-05-10 | -$8.49M derived: sum of 2 quarters · filed 2023-05-10 | -$11.07M derived: sum of 3 quarters · filed 2023-05-10 | -$12.62M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$4.62M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | -$7.21M derived: sum of 2 quarters · filed 2023-03-10 | -$8.76M derived: sum of 3 quarters · filed 2023-03-10 | -$10.43M 10-K · filed 2023-03-10 |
| 2021-09-30 | -$2.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | -$4.14M derived: sum of 2 quarters · filed 2022-11-14 | -$5.81M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | -$1.55M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$3.22M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$1.67M 10-Q · filed 2022-05-12 | |||
| 2020-12-31 | -$6.81M 10-K · filed 2022-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Lunai Bioworks Inc. (LNAI) | United States | $0.072B | -0.11 |
| PMV Pharmaceuticals, Inc. (PMVP) | United States | $0.071B | -0.95 |
| TENAX THERAPEUTICS, INC. (TENX) | United States | $0.071B | -7.17 |
| PLIANT THERAPEUTICS, INC. (PLRX) | United States | $0.071B | -0.76 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |